E1505: A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) -IIIA Non-Small Cell Lung Cancer (NSCLC)

Study Status

Open to Enrollment

Study Description

This clinical trial is for patients with non-small cell lung cancer (NSCLC) that has been removed by a surgeon. The study is being done because even with the most aggressive after-surgery treatment with chemotherapy, many people still have the lung cancer come back.

The purpose of this study is to determine if adding the new drug bevacizumab to chemotherapy improves the chance for cure for patients who have had surgery for lung cancer. The study will compare bevacizumab plus chemotherapy to standard chemotherapy alone to see which is better at preventing the cancer from coming back.

All patients in the study will receive the standard form of chemotherapy for NSCLC, given as an outpatient.

Bevacizumab works by preventing the formation of new blood vessels, including those that surround and supply cancer cells. By taking away the blood supply, drugs like bevacizumab may reduce tumor cell growth and cause cancerous tumors to grow more slowly or become smaller.

Patients will be randomly assigned to one of two study arms:

  • Arm A: if you are assigned to Arm A treatment will be with one of four chemotherapy regimens which will be chosen by you and your study physician
  • Arm B: if you are assigned to Arm B you will receive the same chemotherapy as those on Arm A plus the addition of bevacizumab

Patients randomized to Arm A (chemotherapy treatment) will likely be on the study for about 3 months. Patients randomized to Arm B (chemotherapy and bevacizumab) will likely be in the study for about 1 year.


Eastern Cooperative Oncology Group

Key Eligibility

  • Men and women age 18 and older
  • Non-small cell lung cancer (NSCLC) stage IB - IIIA
  • Have had complete resection of NSCLC (surgically removed)
  • No prior chemotherapy
  • No hormonal cancer or radiation therapy within the past 5 years
  • Detailed eligibility reviewed when you contact the study team

Principal Investigator

Bryan Schneider, MD


  • Physician's office
  • (646) 962-2066

Healthy Volunteers


As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Erica Bersin
Tel: (646) 962-8232
[email protected]

Top of page